Inaktiver Wert

Andere Sprachen Organovo Holdings Inc Nyse

Aktien

US68620A1043

Schlusskurs Nyse Andere Börsenplätze
- ^USD	-

31.05.	Organovo Holdings, Inc. meldet Ergebnis für das am 31. März 2024 endende Geschäftsjahr	CI
15.04.	Organovo's Medikament gegen Fettlebererkrankung erreicht Hauptziel in Mid-Stage-Studie	RE

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Organovo Holdings, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	31.05.
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease	21.05.
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)	14.05.
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering	09.05.
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	16.04.
Organovo's fatty liver disease drug meets main goal in mid-stage study	15.04.
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	15.04.
Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	15.04.
Organovo: Fiscal Q3 Earnings Snapshot	08.02.
Organovo Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	08.02.
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress	25.01.
Organovo Holdings, Inc. Presents FXR314 3D Human Tissue Model Findings	25.01.
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress	09.01.
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results	06.12.
Organovo Holdings, Inc. Provides Timing for Release of FXR314 Phase 2 NASH Results	06.12.
Organovo: Fiscal Q2 Earnings Snapshot	10.11.
Organovo Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09.11.
Organovo Highlights FXR314 Combination Therapy Potential and Plan	08.11.
Organovo Holdings, Inc. Highlights FXR314 Combination Therapy Potential and Plan	08.11.
Organovo : Submission of Matters to a Vote of Security Holders - Form 8-K	03.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Organovo Holdings Inc Nyse

Aktien

US68620A1043

Andere Sprachen

Filter